Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock

Vertex just laid claim to an asset that might be very valuable.Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (VRTX -0.92%) announced it would purchase Alpine Immune Sciences (ALPN -0.05%) for $4.9 billion in cash in a deal that's set to close before the end of this quarter. The prized asset that Vertex will gain as part of this purchase is ALPN-303, a potential autoimmune treatment that's in phase 2 clinical trials.But there's a lot more to the deal's potential value ...